Monoclonal antibody directed against endothelial cell marker (CD31, JC70), capable of evaluating tumour angiogenesis and angiosarcoma more effectively than anti-FVIII-Reg.
| Inventor | Institute |
|---|---|
| Jacqueline Cordell | University of Oxford |
| Cat. #: | 151357 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction;Stem cell biology;Tissue-specific biology |
| Application: | FACS ; IHC ; IF ; WB |
| Target: | PECAM1 (CD31) |
| Reactivity: | Human |
| Clone: | JC70 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Platelet/Endothelial Cell Adhesion Molecule 1; CD31 Antigen; EndoCAM; PECAM-1; GPIIA; PECA1; CD31/EndoCAM; CD31 |
|---|---|
| Product description: | Monoclonal antibody directed against endothelial cell marker (CD31, JC70), capable of evaluating tumour angiogenesis and angiosarcoma more effectively than anti-FVIII-Reg. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Cell membrane preparation from the spleen of a patient with hairy cell leukaemia |
| Immunogen Uniprot ID: | P16284 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | CD31/JC70, also known as platelet endothelium cell adhesion molecule (PECAM-1), is a 130kDa transmembrane glycoprotein found on cell surface of endothelial cells, platelets, macrophages and Kupffer cells, granulocytes, lymphocytes (T cells, B cells, and NK cells), megakaryocytes, and osteoclasts. PECAM1 is a member of the immunoglobulin (Ig) superfamily. It is also a major constituent of the endothelial cell intercellular junction and expressed in certain cancers. PECAM1 is involved in cell signalling and adhesion, trans-endothelial migration of leukocytes, angiogenesis, and integrin activation. PECAM1 is a specific marker of endothelial differentiation. Anti-CD31 be used to identify the presence of endothelial cells in a histological tissue sample to determine the degree of angiogenesis (which in turn can determine tumour severity/growth). Anti-CD31 stains a fixation resistant epitope on endothelial cells in both benign and malignant endothelial cells in angiosarcomas with more consistency than monoclonal or polyclonal antibodies to FV111-Rag . CD31 is a good marker of endothelial cells in paraffin sections. Anti-CD31 was created to recognise membrane bound glycoprotein CD31/JC70. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Muller WA, Kishimoto T, et al (eds) 1997. Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 362-364. ISBN-13: 978-0815327455 Thomson et al. 2018. Methods Mol Biol. 1846:153-160. PMID: 30242758. Ceasrine et al. 2018. Elife. 7:. PMID: 30303066. Frye et al. 2018. Nat Commun. 9(1):1511. PMID: 29666442. Fujita et al. 2017. PLoS One. 12(9):e0184534. PMID: 28886194. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Woei-A-Jin et al. 2016. Br J Cancer. :. PMID: 27404454. Tsuneki et al. 2015. Lab Invest. :. PMID: 25961170. A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway. Zhao et al. 2013. Cancer Res. 73(20):6149-63. PMID: 24097821. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Ding et al. 2013. PLoS One. 8(5):e63628. PMID: 23675495. HIF-1a transgenic bone marrow cells can promote tissue repair in cases of corticosteroid-induced osteonecrosis of the femoral head in rabbits. Orecchia et al. 2011. PLoS One. 6(9):e24307. PMID: 21931678. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. Parums et al. 1990. J Clin Pathol. 43(9):752-7. PMID: 2212067. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.